Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Elective lymph node dissection in melanoma: still a controversial issue.

B B Kroon1, A Jonk

  • 1Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Huis, Amsterdam.

The Netherlands Journal of Surgery
|August 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single intralesional tracer dose for radio-guided excision of clinically occult breast cancer and sentinel node.

Annals of surgical oncology·2002
Same author

Sensitivity of sentinel node biopsy in melanoma.

Journal of surgical oncology·2001
Same author

The European Society of Surgical Oncology.

Surgical oncology clinics of North America·2001
Same author

Isolated limb perfusion: the European experience.

Surgical oncology clinics of North America·2001
Same author

The definition of a sentinel node.

Annals of surgical oncology·2001
Same author

Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2001

The management of regional lymph nodes in melanoma patients remains controversial, especially for tumors between 1.5 and 4 mm thick. Further research is needed to determine the optimal strategy for elective lymph node dissection.

Area of Science:

  • Oncology
  • Dermatology
  • Surgical Oncology

Background:

  • Regional lymph node status is critical in melanoma staging and prognosis.
  • Current guidelines vary regarding lymph node management for intermediate-thickness melanomas (1.5-4 mm).
  • Elective lymph node dissection (ELND) is standard for thick melanomas (>4 mm) but its benefit is debated.

Purpose of the Study:

  • To review the current evidence and controversies surrounding elective lymph node dissection in primary melanoma patients.
  • To highlight the lack of consensus for melanomas with Breslow thickness between 1.5 and 4 mm.
  • To identify the need for further research and prospective studies.

Main Methods:

  • Review of existing literature, including prospective trials and retrospective studies.

Related Experiment Videos

  • Analysis of arguments for and against elective lymph node dissection in specific melanoma thickness categories.
  • Discussion of the impact of micrometastases on patient survival.

    • Main Results:

    • For melanomas ≤1.5 mm thick, clinically unsuspected lymph nodes are typically left untreated.
    • For melanomas >4 mm thick, ELND has minimal impact on survival due to frequent distant micrometastases.
    • There is no consensus on ELND for melanomas between 1.5 and 4 mm, with conflicting evidence from different study types.

    Conclusions:

    • The optimal management strategy for regional lymph nodes in patients with primary melanoma, particularly those with intermediate tumor thickness, remains undetermined.
    • Further high-quality prospective comparative studies are essential to establish the benefit of elective lymph node dissection.
    • Advancements in detecting occult lymph node metastases are needed to guide clinical decision-making.